Combination treatment for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the stomach or the area where the stomach meets the food pipe that cannot be removed by surgery.
- You are between 18 and 75 years old.
- You are generally able to care for yourself and do everyday tasks (ECOG score 0 or 1).
- You have not had chemotherapy or radiation for this cancer before.
- Your cancer is HER2 negative (a specific marker).
- Your major organs (like kidneys, liver, and blood cells) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This study looks at combining chemotherapy, immunotherapy, and a targeted drug called fruquintinib before surgery for people with stomach cancer that has spread. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.